Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection
Hans‐Uwe Simon, А. В. Караулов, Martin F. Bachmann
Abstract
A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology.
Topics & Concepts
ImmunologyMedicineEosinophilVaccinationCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunopathology2019-20 coronavirus outbreakDiseaseVirologyAsthmaInfectious disease (medical specialty)OutbreakPathologyInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisEosinophilic Disorders and SyndromesRespiratory viral infections research